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Abstract
Purpose: To assess whether an expanded (five level) risk stratification system can be used to
identify the sub-group of intermediate risk patients with prostate cancer who benefit from
combining androgen deprivation therapy (ADT) with external beam radiotherapy (EBRT).
Materials and methods: Using a previously validated 5-risk group schema, a prospective non-
randomized data set of 1423 men treated at the British Columbia Cancer Agency was assessed for
the primary end point of biochemical control (bNED) with the RTOG-ASTRO "Phoenix" definition
(lowest PSA to date + 2 ng/mL), both with and without adjuvant ADT. The median follow-up was
5 years.
Results: There was no bNED benefit for ADT in the low or low intermediate groups but there
was a statistically significant bNED benefit in the high intermediate, high and extreme risk groups.
The 5-year bNED rates with and without ADT were 70% and 73% respectively for the low
intermediate group (p = non-significant) and 72% and 58% respectively for the high intermediate
group (p = 0.002).
Conclusion: There appears to be no advantage to ADT where the Gleason score is 6 or less and
PSA is 15 or less. ADT is beneficial in patients treated to standard dose radiation with Gleason 6
disease and a PSA greater than 15 or where the Gleason score is 7 or higher.
Background
Androgen deprivation therapy (ADT) has a proven role in
the treatment of metastatic prostate cancer. Some groups
of patients undergoing external beam radiotherapy
(EBRT) for localized prostate cancer also benefit from
adjuvant ADT. An EORTC trial randomized patients with
T1–2 high grade or T3–4 N0–1 prostate cancer to either
radiotherapy alone or with 3 years of ADT and showed an
improved overall survival at 5 years[1]. The Trans-Tasman
Radiation Oncology Group 96.01 trial randomized
patients with T2b-T4 N0 disease to radiotherapy alone or
with 3 or 6 months ADT. There was an improvement in
disease free survival for both ADT arms compared to EBRT
alone [2].
Sub-division of prostate cancer patients into risk groups
can be used to guide management decisions based on
their risk of relapse. The National Comprehensive Cancer
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Network (NCCN) classifies three risk groups: Low risk
(T1-T2a, Gleason score ≤ 6 and PSA ≤ 10 ng/ml), Interme-
diate risk (T2b-T2c or Gleason score 7 or PSA 10.1–20 ng/
ml) and High risk (≥ T3a or Gleason 8–10 or PSA > 20 ng/
ml) [3]. When localized prostate cancer is divided into
three risk groups, an improvement in the biochemical
control rate (bNED) at 5 years has been documented in
the intermediate and high risk groups by the addition of
neo-adjuvant ADT to EBRT [2,4]. However, a high hetero-
geneity of outcomes within the intermediate risk patient
group has been demonstrated [5]. As ADT causes poten-
tially significant morbidity, it would be desirable to iden-
tify within the intermediate risk group a lower risk sub-
group who can avoid ADT without compromising cancer
control. A five-level risk stratification system with
expanded intermediate risk divisions has previously been
developed using recursive partitioning analysis and exter-
nally validated [6] (see Table 1). The aim of the present
study is to determine if these five patient subgroups can
better identify those who benefit from the combination of
ADT with EBRT.
Methods
A prospective non-randomized patient data set was ana-
lyzed, comprising 1583 men treated with EBRT between
1994 and 2001 identified from the Prostate Cohort Out-
comes Initiative Database of the British Columbia Cancer
Agency (BCCA). After exclusions descried below, 1423
men were available for analysis. All patients received rad-
ical EBRT with photon irradiation and CT planning. Those
treated with hypofractionated radiation (50–55 Gy in 20
fractions, n = 133) were excluded, as were those who had
neoadjuvant ADT of duration <2 months or >12 months,
n = 24. Three-dimensional conformal radiotherapy was
used from 1998. The median dose administered was 66
Gy (range 66 – 72 Gy) in 2 Gy fractions. Most patients
were treated with small volumes to the prostate alone but
177 patients also had a first phase with whole pelvic radi-
otherapy. Three patients enrolled in a study of ADT versus
ADT and EBRT (National Cancer Institute of Canada PR3
study) were excluded.
Patients with higher risk cancers were often selected for
combined therapy with neoadjuvant ADT and radiation,
but there was no formal policy governing this until 1997.
Additionally, because of waiting lists in the early 1990's
men with lower risk cancers were also given ADT. Prior to
1997, ADT was delivered by a combination of low-dose
stilboestrol (0.1 mg) and cyproterone acetate (50 mg),
which has been shown to provide castrate levels of testo-
sterone [7], subsequently LHRH agonist injections (with
initial anti-androgen to suppress any androgen flare) were
used. Total androgen blockade was not the institutional
policy and was used in less than 5% of patients. ADT use
was mainly neo-adjuvant until 1997. In 1997, when data
was presented showing a benefit from extended adjuvant
ADT in high risk patients [8], the BCCA published guide-
lines [9] and thereafter adjuvant ADT was added to our
prior neoadjuvant practice, for an increased overall dura-
tion of ADT.
Generally, patients were seen every 6 months for 3 years,
then annually for 3 years, then every 2 years. At each visit
clinical examination, PSA and testosterone assays, and
toxicity were scored. Follow-up is timed from the comple-
tion of radiation therapy. Data for all patients was entered
prospectively into the database. Additional PSA results
from other sources, such as general practice requests, were
also incorporated into the database. Institutional ethics
review boards approval was obtained for this study.
The standard risk stratification schema was that of the
National Comprehensive Cancer Network (NCCN) with
three levels: high risk – those with either PSA > 20 ng/mL
or T stage T3 or more, or Gleason score 8–10; low risk –
those with a PSA <10 ng/mL and T2a or less stage, and GS
6 or less; intermediate risk – all those not high or low risk.
Our five level investigational risk schema is shown in
Table 1.
The primary endpoint for the study is the absence of bio-
chemical evidence of disease (bNED), which has been
shown to be an independent predictor of overall survival
when radiotherapy alone has been used to treat prostate
cancer [10] and is frequently used as a early end-point in
studies of prostate cancer. Patients in this study were
assessed for the primary endpoint of biochemical control
with the "Phoenix" (lowest PSA to date +2 ng/mL) bNED
criterion, as this is robust with or without the use of ADT,
unlike the ASTRO definition which is not recommended
for studies using ADT[11]. Overall survival (OS) and
cause-specific survival (CSS) were obtained from direct
data linkage with provincial and national death registries.
Assigned deaths due to prostate cancer in the absence of
known metastatic relapse, or death from another cause in
the presence of known metastatic prostate cancer, were
checked manually by chart review.
Table 1: Five Level Risk Stratification for prostate cancer. [6]
Risk Factor
Risk Group PSA Gleason T-Stage
1. Low <7.5 ≤ 6a n y
2. Low-intermediate 7.5–15 ≤ 6a n y
3. High-intermediate 15–20 ≤ 6a n y
≤ 10 ≥ 7a n y
4. High 20–30 ≤ 6a n y
10–20 ≥ 7a n y
5. Extreme >20 ≥ 7a n y
>30 ≤ 6a n yRadiation Oncology 2008, 3:8 http://www.ro-journal.com/content/3/1/8
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Comparison of patient characteristics was made using chi-
squared tests for categorical data and Kruskal-Wallis tests
for non-parametric tests. Time to end-point events was
derived using the Kaplan-Meier technique with corre-
sponding log-rank tests of significance. Patients were cen-
sored at the time of last clinical follow-up. P values of
<0.05 were considered significant.
Results
The median follow-up was 5 years for biochemical status,
(range 1 month – 11 years) and 7.7 years for survival,
range 3 months – 12 years). Patient characteristics by
expanded and NCCN risk groups are shown in table 2.
ADT was used more frequently and for progressively
longer durations in higher risk groups.
The Kaplan-Meier survival curves for biochemical control
by NCCN risk groups are presented in figure 1. In the low
risk group there was no difference in 5 year bNED
between the patients treated with ADT and without (92%
versus 85% respectively, p = 0.33). In the intermediate risk
group the 5 year bNED rate was significantly higher in the
patients treated with ADT at 82% compared to those
treated without at 70% (p = 0.003). In the high risk group
there was also a difference between those treated with and
without ADT, 55% versus 42% respectively (p = 0.004).
With the expanded 5-risk grouping significant differences
in bNED was seen in the high-intermediate, high and
extreme risk groups but not the low and low-intermediate
risk groups (figure 2 and table 3). For the low intermedi-
ate group 5 year bNED survival was 75% with ADT and
70% without (p = 0.43). For the high intermediate group
5 year bNED survival was 72% with ADT and 55% with-
out (p = 0.0025). There was no significant effect on cancer
specific survival or overall survival for any group.
Discussion
The use of androgen deprivation therapy in combination
with EBRT has increased substantially over recent years,
with, for example, data from the Cancer of the Prostate
Strategic Urologic Research Endeavor (CAPSURE) in the
United States suggesting that the rate of use has increased
from 9.8% to 74.6% between 1989–1990 and 2000–
2001[12]. This is undoubtedly related to several large ran-
domized clinical trials which have shown a benefit to the
combined treatment. This increased usage is paralleled by
substantial toxicity related to castrate physiology, with
physical, psychological and sexual side effects often being
detrimental to a patient's quality of life. With these issues
in mind, we demonstrated that there is potential to
improve the selection of patients for treatment with com-
bined hormonal manipulation based on contemporary
knowledge of outcome prognostication.
To date, accurately identifying which patients will benefit
from the addition of ADT to EBRT has been difficult, due
to inter-trial differences in factors such as the stage and
grade of the patients, dose and volume of radiation and
the duration and timing of ADT. In terms of the tumour
characteristics, most early studies have focused on
patients with locally advanced disease. The Radiation
Table 2: Patient characteristics from the Prostate Cohort Outcomes Initiative Database of the British Columbia Cancer Agency 
(BCCA) sorted by NCCN risk groups [3] and 5-level risk stratification. [6]
Expanded Risk Groups (Williams, Duchesne,2006) NCCN Risk Groups
Low (n = 317) Low-intermediate 
(n = 293)
Intermediate 
(n = 329)
High (n = 241) Extreme 
(n = 230)
Low (n = 229) Intermediate 
(n = 497)
High (n = 677)
PSA
Median 4.9 10.1 7.7 15.8 36 6.1 9.8 16
Range 0.2–7.5 7.6–15 0.3–20 10.1–30 20–250 0.2–10 0.3–20 0.5–250
T stage
T1 70 77 46 22 23 116 82 40
T2 187 151 150 111 62 113 415 134
T3 56 58 126 97 121 0 0 462
T 4 2357 1 5 00 3 2
m i s s i n g 24249009
Age
Median 71 72 71 71 69 71 72 70
Age range 46–84 50–82 49–86 47–85 48–82 54–84 50–86 46–84
EBRT dose
Median (Gy) 66 66 66 66 66 66 66 66
Range (Gy) 66–70 66–70 66–72 66–72 66–70 66–70 66–72 66–72
Gleason score
6 or less 317 293 74 61 44 229 308 246
7 0 0 175 135 109 0 189 227
8 or more 0 0 80 45 77 0 0 205
ADT rate [Neoadjuvant 
alone, neoadjuvant-adjuvant]
19.2% [72%, 28%] 23.5% [55%, 45%] 51.7% [39%, 61%] 62.2% [36%, 64%] 79.6% [41%, 59%] 13.5% [87%, 13%] 25.4% [47%, 53%] 69.7% [40%, 60%]
Duration of ADT 
(neoadjuvant ADT) mean, 
[total SD] in months)
8.3 (1.1) [6.0] 10.8 (1.5) [7.3] 15.4 (3.2) [13.9] 15.4 (4.0) [13.4] 17.3 (4.7) [16.7] 7.0 (0.8) [3.4] 11.9 (1.6) [12.0] 16.2 (4.3) [14.5]Radiation Oncology 2008, 3:8 http://www.ro-journal.com/content/3/1/8
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Kaplan Meier curve for bNED (biochemical lack of evidence of disease survival) according to NCCN risk groups [3]. Black lines  show combined EBRT and ADT, grey lines EBRT alone Figure 1
Kaplan Meier curve for bNED (biochemical lack of evidence of disease survival) according to NCCN risk 
groups [3]. Black lines show combined EBRT and ADT, grey lines EBRT alone. P values refer to the log-rank test.
Table 3: 5-year biochemical lack of evidence of disease (bNED) in patients treated for prostate cancer with EBRT sorted by 5-level risk 
stratification, with the hazard ratio of relapse with/without ADT and corresponding p values are generated from the Kaplan-Meier log-
rank test.
Risk Group With ADT Without ADT Hazard ratio [95% CI] P value
Low 84% 86% 1.8 [0.2–16.6] n.s
Low intermediate 75% 70% 1.1 [0.56–2.1] n.s
High intermediate 72% 55% 0.57 [0.4–0.83] P = 0.0029
High 64% 36% 0.47 [0.33–0.69] P = 0.0001
Extreme 43% 21% 0.61 [0.42–0.89] P = 0.01Radiation Oncology 2008, 3:8 http://www.ro-journal.com/content/3/1/8
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Kaplan Meier curve for bNED (biochemical lack of evidence of disease survival) according to expanded risk group [6] Figure 2
Kaplan Meier curve for bNED (biochemical lack of evidence of disease survival) according to expanded risk 
group [6]. 5-year bNED rates and hazard ratios are in Table 3. Black lines show combined EBRT and ADT, grey lines EBRT 
alone. P values refer to the log-rank test.Radiation Oncology 2008, 3:8 http://www.ro-journal.com/content/3/1/8
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Therapy Oncology Group (RTOG) 86–10 study [13] ran-
domized patients with bulky primary cancers to either 2
months neoadjuvant and 2 months concurrent ADT with
EBRT or EBRT alone. There was improved bNED and local
control at 8 years with the addition of ADT, and the sub-
group with Gleason score 2–6 cancers (many notably
lacked baseline PSA levels) had a statistically improved
overall survival at 70% compared to 52% with EBRT
alone. Similarly, locally advanced (T3–4) or node positive
cancers were included in EORTC 22863 [1] and RTOG
85–31 [14] trials, and randomized to have either immedi-
ate long term ADT starting at EBRT completion, or obser-
vation with delayed ADT. Overall survival was improved
from 62% to 78% at five years in the EORTC trial (p =
0.0002), and improved in the Gleason score 8–10 subset
of the RTOG trial. The Trans-Tasman Radiation Oncology
Group (TROG) 96.01 trial of locally advanced prostate
cancer [2] showed a benefit of adding ADT in terms of
local failure, bNED, disease free survival and freedom
from salvage treatment for both 3 and 6 months of neoad-
juvant ADT.
Possibly more relevant to contemporary cohorts, the trial
by D'Amico et al [15] randomized 206 patients with T1b
– T2b tumors with a Gleason score greater than 6 to either
EBRT (70 Gy) alone or EBRT with 6 months ADT. After an
average follow-up of 4.5 years the estimated overall sur-
vival at 5 years was 88% for the combined treatment arm
compared to 78% for radiotherapy alone (p = 0.04). There
were only 6 prostate-cancer deaths in this trial, and given
the small patient numbers the results should be treated
with caution until replicated. Overall however, the general
evidence appears to be in favour of the addition of ADT to
EBRT in many prostate cancers, and a variety of ADT dura-
tions have resulted in significant gains.
Logically, the duration of ADT has since become the focus
in a number of studies. A Canadian study which included
T1c-T4 tumors, compared 3 and 8 months neo-adjuvant
ADT and showed improvements in cause-specific survival
in a high risk sub-set with longer ADT durations, accord-
ing to a recent oral update of a prior publication [16]. The
RTOG 92–02 study looked at more prolonged ADT, com-
paring 4 months with 24 months. This showed improve-
ments in local control, bNED, cause-specific survival and
freedom from distant metastases with prolonged ADT but
an overall survival benefit was only seen for those with
Gleason score 8 – 10. This benefit, curiously, was only
seen in those with community-generated pathology
reports, and was no longer present after central
review[17]. TROG 96.01 also suggested cancer specific
survival was also improved with 6 months ADT rather
than zero or three months [2]. A further large TROG study
("RADAR") comparing 6 with 18 months ADT has fin-
ished accrual. The net result of these mixed studies is that
ADT is used almost universally in high risk cancers, and
also for intermediate risk in many centres. Using these
standard NCCN criteria our data further reinforces these
findings. Additionally, we suggest that by using an alter-
native risk stratification, the bNED benefit of additional
ADT is confined to the high-intermediate, high and
extreme risk groups.
No significant effect on cancer specific or overall survival
was able to be demonstrated. This may be because the fol-
low-up is too short and/or it may reflect the relatively high
short-term efficacy of salvage ADT. Another possible
explanation could be that the ADT duration for the high
and extreme risk groups was insufficient. Prolonging the
duration of ADT appears to benefit patients with a higher
chance of relapse following EBRT [18,19]. A previous
analysis from our institution also demonstrated an advan-
tage to prolonged, rather than shorter ADT duration (6
months versus 12 versus 24 months) in patients with
localized disease and a PSA above 20 [20]. In our current
study however, the mean durations of ADT for the high
and extreme risk groups were 15 months and 17 months
respectively and the median duration of ADT treatment
was only 11 months in both groups. However these criti-
cisms do not affect our main conclusions, in that a bNED
benefit is a necessary precursor to a survival benefit, and
no bNED benefit was seen in the low-intermediate group.
The study presented here used prospectively collected data
but a valid criticism of the comparison made is that it is
not a randomized trial. There was likely case selection
between those patients who received ADT and those who
did not. A further issue is that the doses of radiation that
were used, while typical for the era, are below contempo-
rary levels. Whether or not dose-escalation beyond the
doses used in the era of this study (66–70 Gy) would obvi-
ate any benefit of ADT in higher risk cancers is currently
unknown, although subject to ongoing randomized trials.
Improved bNED rates seen with escalated doses of radia-
tion would suggest that the benefit might be less than that
achieved with ADT. For example the absolute improve-
ment in Phoenix bNED with 78 Gy versus 68 Gy in the
Dutch randomized trial was 6% [21], which is substan-
tially less than that observed from additional use of ADT
in the present study for higher risk cancers where the
bNED improvement was 18–28% depending on risk. Pos-
sibly, according to risk category, the strategies of dose
escalation and ADT will work in different ways, and it
would be logical to suppose that lower risk cancers have
more to gain form dose escalation, and higher risk cancers
from both ADT as well as dose escalation. Furthermore,
previous trials of prolonged ADT in very advanced cancers
have been criticized because they do not have an ADT-
only arm. The National Cancer Institute of Canada PR3/
Medical Research Council (UK) study, which randomizedRadiation Oncology 2008, 3:8 http://www.ro-journal.com/content/3/1/8
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patients with locally advanced disease between ADT and
ADT + EBRT, is yet to report, but should address this crit-
icism.
ADT often causes significant side effects. During therapy,
patients can suffer hot flashes, weight gain, gynaecomas-
tia, impotence, loss of libido, fatigue and depression
[22,23]. Longer-term side effects include a significant loss
of bone mineral density after a year of ADT [24] and
increased fracture rates with more prolonged durations of
ADT[25]. A recently published study using the SEER data-
base has demonstrated a significantly increased risk of
developing incident diabetes, coronary heart disease,
myocardial infarction and sudden cardiac death in men
with prostate cancer who received ADT, when compared
with those who did not [26] Even short durations of
LHRH agonist therapy (1–4 months) were shown to carry
increased risk of incident diabetes and coronary heart dis-
ease. D'Amico etc [27] has also shown increased fatal MI
rates in those aged >65 years, with even short term ADT.
There may also be adverse cognitive effects after 6 months
of ADT [28]. Considering all these potential morbidities,
ADT should be reserved for those with the highest chance
of net benefit.
Overall, trials looking at the combination of ADT and
EBRT have shown the greatest benefits for patients with
locally advanced or high-grade tumors. This is reflected by
our practice, in that higher risk patients were more likely
to receive ADT. This was also the case in another retro-
spective review published recently [29]. The benefit of
ADT in lower risk groups remains more controversial, and
an improvement in bNED was not demonstrated in our
dataset for low and low-intermediate risk patients. There-
fore, these men (comprising 43%, of our cohort) may be
safely spared the additional toxicity of ADT without com-
promising tumour control.
Conclusion
This analysis divides the intermediate risk patients with
localized prostate cancer and identifies the sub-groups
who do, and do not obtain a bNED benefit from ADT.
There appears to be no advantage to ADT where the
Gleason score is 6 or less and PSA is 15 or less. ADT pro-
vides a bNED benefit in patients treated to standard dose
radiation with Gleason 6 disease with a PSA greater than
15 or where the Gleason score is higher than 6.
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